The Lancet Breast Cancer Commission
2024 · The Lancet · 132 citations
https://doi.org/10.1016/s0140-6736(24)00747-5
F
Farasat Kazmi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
82
Papers
616
Citations
10
h-index
11
i10-index
Farasat Kazmi is an academic researcher from Norfolk and Norwich University Hospital. The author has contributed to research in topics: HIV/AIDS drug development and treatment & Lung Cancer Treatments and Mutations & Biochemical and Molecular Research. The author has an h-index of 10, co-authored 70 publications.
ORCID: 0000-0003-1666-2861Papers by this author
worksNext-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer
2025 · Cochrane Database of Systematic Reviews · 5 citations
https://doi.org/10.1002/14651858.cd014872.pub2
169P Tumour microenvironment in glioblastoma: A single-cell perspective on macrophage dynamics and T cell exhaustion
2024 · ESMO Open · 0 citations
https://doi.org/10.1016/j.esmoop.2024.103906
Supplementary Figure 2E from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27902404
Table S3 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27902380
Table S2 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27902383
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat